Genentech Seeks Expanded Use of Avastin in Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Genentech Seeks Expanded Use of Avastin in Breast Cancer

SAN FRANCISCO, Calif—Genentech has submitted an application to the FDA for expanded use of bevacizumab (Avastin) in combination with taxane chemotherapy for treatment of chemotherapy-naïve recurrent or metastatic breast cancer. Phase III data showed that patients who received bevacizumab in combination with paclitaxel had a 52% reduction in risk of disease progression or death, compared to those who received paclitaxel alone.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content